Persistence with teriparatide in patients with osteoporosis: the UK experience
Persistence with teriparatide in patients with osteoporosis: the UK experience
INTRODUCTION: The objective of this paper was to determine the persistence with teriparatide at 12 months in all patients in the UK who were prescribed the treatment since its launch.
METHODS: Virtually all patients prescribed teriparatide in the UK receive treatment through Healthcare at Home, Basingstoke, UK. Data was obtained to assess the start date, discontinuation date and reason for discontinuation in all patients receiving teriparatide since its launch. Persistence was defined as the number of patients continuing treatment.
RESULTS: A total of 1,104 patients were included in the analysis. The median duration of use in all patients was 252 days. Of the 435 patients who were at least 12 months post-initiation of treatment, persistence was 87%. Forty-two patients (3.8%) had discontinued treatment due to adverse events.
CONCLUSIONS: This study demonstrates that persistence with teriparatide at 12 months is very high and is probably greater than that of existing oral therapies for osteoporosis. The reasons for the high persistence rates seen with teriparatide are likely to be multi-factorial. The high persistence rates should help to optimise the effectiveness of therapy in this group of high-risk patients.
therapy, analysis, osteoporosis, methods, teriparatide, bone
1626-1629
Arden, N.K.
23af958d-835c-4d79-be54-4bbe4c68077f
Earl, S.
a88a88b7-5b6b-4c8c-9b1a-236167141ed4
Fisher, D.J.
a22f14ff-7cc9-4e74-ae56-85b0f8b648cc
Cooper, C.
e05f5612-b493-4273-9b71-9e0ce32bdad6
Carruthers, S.
4fd8de59-b170-4b01-95e4-6ec0f235ebcb
Goater, M.
6dfecfa4-1d8e-4ae7-ba7e-bf1ab157ae48
2006
Arden, N.K.
23af958d-835c-4d79-be54-4bbe4c68077f
Earl, S.
a88a88b7-5b6b-4c8c-9b1a-236167141ed4
Fisher, D.J.
a22f14ff-7cc9-4e74-ae56-85b0f8b648cc
Cooper, C.
e05f5612-b493-4273-9b71-9e0ce32bdad6
Carruthers, S.
4fd8de59-b170-4b01-95e4-6ec0f235ebcb
Goater, M.
6dfecfa4-1d8e-4ae7-ba7e-bf1ab157ae48
Arden, N.K., Earl, S., Fisher, D.J., Cooper, C., Carruthers, S. and Goater, M.
(2006)
Persistence with teriparatide in patients with osteoporosis: the UK experience.
Osteoporosis International, 17 (11), .
(doi:10.1007/s00198-006-0171-5).
Abstract
INTRODUCTION: The objective of this paper was to determine the persistence with teriparatide at 12 months in all patients in the UK who were prescribed the treatment since its launch.
METHODS: Virtually all patients prescribed teriparatide in the UK receive treatment through Healthcare at Home, Basingstoke, UK. Data was obtained to assess the start date, discontinuation date and reason for discontinuation in all patients receiving teriparatide since its launch. Persistence was defined as the number of patients continuing treatment.
RESULTS: A total of 1,104 patients were included in the analysis. The median duration of use in all patients was 252 days. Of the 435 patients who were at least 12 months post-initiation of treatment, persistence was 87%. Forty-two patients (3.8%) had discontinued treatment due to adverse events.
CONCLUSIONS: This study demonstrates that persistence with teriparatide at 12 months is very high and is probably greater than that of existing oral therapies for osteoporosis. The reasons for the high persistence rates seen with teriparatide are likely to be multi-factorial. The high persistence rates should help to optimise the effectiveness of therapy in this group of high-risk patients.
This record has no associated files available for download.
More information
Published date: 2006
Keywords:
therapy, analysis, osteoporosis, methods, teriparatide, bone
Identifiers
Local EPrints ID: 60870
URI: http://eprints.soton.ac.uk/id/eprint/60870
ISSN: 0937-941X
PURE UUID: 029879cf-e01f-4049-964e-bc8fcf1d69c3
Catalogue record
Date deposited: 09 Sep 2008
Last modified: 18 Mar 2024 02:44
Export record
Altmetrics
Contributors
Author:
S. Earl
Author:
D.J. Fisher
Author:
S. Carruthers
Author:
M. Goater
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics